Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Orthofix Medical (OFIX) EBITDA Margin (2016 - 2025)

Orthofix Medical (OFIX) has disclosed EBITDA Margin for 16 consecutive years, with 42.24% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 3854.0% year-over-year to 42.24%, compared with a TTM value of 11.26% through Dec 2025, up 1205.0%, and an annual FY2025 reading of 11.26%, up 488.0% over the prior year.
  • EBITDA Margin was 42.24% for Q4 2025 at Orthofix Medical, down from 10.06% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 92.33% in Q4 2023 and bottomed at 80.78% in Q4 2024.
  • Average EBITDA Margin over 5 years is 2.34%, with a median of 1.81% recorded in 2025.
  • The sharpest move saw EBITDA Margin surged 6167bps in 2021, then tumbled -17310bps in 2024.
  • Year by year, EBITDA Margin stood at 55.52% in 2021, then soared by 51bps to 83.67% in 2022, then rose by 10bps to 92.33% in 2023, then crashed by -187bps to 80.78% in 2024, then soared by 48bps to 42.24% in 2025.
  • Business Quant data shows EBITDA Margin for OFIX at 42.24% in Q4 2025, 10.06% in Q3 2025, and 5.55% in Q2 2025.